Some studies have shown that increased blood glucose and advanced glycation end products (AGEs) can down-regulate the expression/activity [203] of eNOS through inflammation [204], and redox pathway [205].T2D can lead to elevated cytokine levels (e.g., TNF-α) and further downregulate eNOS expression [206]. The gene discussed is NOS3; the disease is type 2 diabetes mellitus.